Tetraphase Pharmaceuticals has entered into an exclusive licensing agreement with Everest Medicines to develop and commercialize eravacycline in mainland China, Taiwan, Hong Kong, Macau, South Korea, and Singapore.   Under the terms of the agreement, Tetraphase will receive an initial upfront payment of $7 million and may receive clinical and regulatory milestones of up to $16.5 million as well as annual sales milestones of up to $20 million. Everest will be solely responsible for the de...